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Abstract
Ventricular  Tachycardia  (VT)  is  a  life  threatening  complication  in  a  patient  with  Cardiac 
Sarcoidosis.  The  management  becomes  extremely  challenging  when  it  is  refractory  to 
traditional anti-arrhythmic drugs. Herein, we describe a case where a 33-year-old patient with 
VT storm, with an implantable cardioverter defibrillator (ICD), was managed by medications, 
sedation, ventilator support and multiple Radio-Frequency (RF) ablation procedures over 76-
days  ICU  stay  period.                                                     
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Introduction
            
Sarcoidosis is a multisystem disease of unknown etiology. With the advent and frequent use of 
current diagnostic modalities, cardiac involvement in sarcoidosis is now frequently diagnosed. 
Cardiac sarcoidosis related arrhythmia can be very difficult to manage. VT is in fact one of the 
most frequent arrhythmias encountered in cardiac sarcoidosis and can be present in up to 23% 
of the patients [1]. Because of increased awareness of the risk of sudden cardiac death and early 
ICD implantation, cardiac sarcoidosis patients can survive to present with VT storm, which is 
not uncommonly resistant to standard anti-arrhythmic drugs. We report a case with a patient 
diagnosed  with  cardiac  sarcoidosis,  suffering  from  refractory  ventricular  tachycardia  (VT) 
resulting in frequent shock therapies from ICD, successfully stabilized by multiple RF ablation 
procedures over two and half months of ICU care.                                          
Case  Presentation                                               
A  33-year-old  man  was  incidentally  detected  to  have  Premature  Ventricular  Contractions 
(PVCs)  during  annual  health  check-up.  There  were  no  other  remarkable  features  in 
electrocardiogram (ECG) or echocardiogram (LVEF 60% and no Right Ventricular disease) in 
January 2011.       Following month, the patient got admitted with palpitations and presyncope, 
and diagnosed with sustained VT, which was alleviated with direct current (DC) cardioversion, 
IV Amiodarone and Beta blockers. Detailed investigations were performed including contrast 
enhanced  computed  tomography  (CECT)  of  chest,  cardiac  MRI,  followed  by  endoscopic 
ultasonography guided fine needle aspiration cytology (FNAC) which were all suggestive of 
sarcoidosis, therefore steroid immunosuppressive therapy was started at this time.                    
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In June 2011, the patient once again presented with sustained rapid monomorphic VT and DC 
cardioversion was performed. Echocardiogram demonstrated left ventricular ejection fraction 
(LVEF) of 15%, LVDd of 64mm, LVDs of 58mm, and grade II mitral  valve regurgitation. 
Dual  chamber  implantable  cardioverter  defibrillator  (ICD)  was  implanted  and  patient  was 
treated with beta blockers, Lidocaine and Amiodarone. Despite anti-arrhythmic drugs (AAD), 
the patient had recurrent VT, which was successfully treated by ICD with 12 shocks in the 
duration of 24 hours.  He was intubated,  placed on ventilatory support and was kept under 
sedation. In addition to AAD, IV Magnesium sulphate and Metoprolol infusions were started. 
The patient  was weaned off  the ventilator  after  3  days  and transferred  to  our  institute  via 
airplane; he received shocks from ICD even during the transfer. Management during ICU stay 
is outlined below (Table 1; Figures 1, 2, 3).
Table 1
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Figure 1: 12 Lead Electrocardiogram showing VT morphology 1
Figure 2: VT2 termination during RF ablation
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Figure 3: Electroanatomical mapping with the CARTO system, composite RV and LV pictures showing sites of 
ablation of 5 VT morphologies
Patient was observed and finally discharged after 76 day of ICU stay. The echocardiogram 
findings  demonstrated  LVEF of  15%,  dilated  Left  Ventricle  and  thinned  out  myocardium. 
During the follow-up (6 months post discharge), patient was performing reasonably well, with 
LVEF of 25%, less frequent non-sustained VT and only one shock from ICD. (Figure 4 shows 
cardiac compass trends of the patient).
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Figure 4: Cardiac compass reports showing marked reduction in VT/VF episodes and increase in patient activity 
following  final  ablation  procedure                                      
Discussion
Sarcoidosis is a multisystem granulomatous disease of unknown etiology characterized by the 
presence of noncaseating granulomas in the involved organs. Cardiac involvement in patients 
with sarcoidosis is getting vastly recognized and is associated with poor prognosis. The clinical 
sequelae  of  cardiac  sarcoidosis  range from asymptomatic  conduction  abnormalities  to  fatal 
ventricular  arrhythmias,  depending  upon  the  location  and  extent  of  granulomatous 
inflammation. Sarcoid granulomas in the ventricular myocardium serve as foci for abnormal 
automaticity  and  cause  changes  in  the  ventricular  activation  and  recovery  process,  which 
explains the reentry mechanism that is thought to lead to VT, the most frequent arrhythmia 
noted  in  cardiac  sarcoidosis  [1].  Some  patients  have  VT  and  concomitant  intermittent 
atrioventricular block, a combination that more typically suggests cardiac Sarcoidosis [2].      
Sarcoidosis that involves the heart warrants prompt therapy with steroids, immunosuppressive 
agents,  or  both  [3].  Steroids  are  believed  to  be  capable  of  attenuating  the  inflammatory 
response and slowing down subsequent fibrosis, but it is less effective in preventing further 
arrhythmia as it is shown to be different inducibility of VT between the active and inactive 
phases of sarcoid heart  disease in  an EP study [1].  Management  of arrhythmias  in cardiac 
sarcoidosis is difficult and effective control of VT often is not achievable by a single method of 
therapy. Current studies recommend cautious use of AAD therapy for ventricular tachycardia 
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in patients with cardiac sarcoidosis as it may result in high rate of recurrence or sudden death. 
Amiodarone use in this  group of patients  may be limited  by the occurrence of  pulmonary 
complications  which  are  often  difficult  to  distinguish  from  pulmonary  sarcoidosis.  Beta 
Blockers also have shown to increase the incidence of heart blocks in patients with cardiac 
sarcoidosis and it becomes more concerning especially if patients have underlying conduction 
blocks on surface ECG prior to the initiation of therapy [4]. Immunosuppressive therapies are 
recommended  as  a  steroid  sparing  strategy  in  the  management  of  sarcoidosis  and  can  be 
beneficial in controlling arrhythmia. Treatment with an ICD along with anti-arrhythmic therapy 
is  mandatory  in  sarcoidosis  patients  with  refractory  VT, who are  at  risk  of  sudden death. 
Prophylactic ICD placement is also recommended in patients with diagnosed sarcoidosis who 
develop  VT  during  exercise  electrocardiography  or  Holter  monitoring  [5].  Implantable 
defibrillators  can  terminate  ventricular  arrhythmias  and  prevent  sudden  death  but  do  not 
prevent these arrhythmias from recurring. Ablation should be considered as an option in those 
patients with recurrent VT that are unresponsive to anti-arrhythmic and immunosuppressive 
agents. RF ablation is very effective in decreasing or eliminating completely episodes of VT in 
a patient with cardiac sarcoidosis. Data from multicenter registry showed that VT burden was 
reduced more than 98% in the first 3 months post ablation in patients with cardiac sarcoidosis; 
the mechanism of VT in virtually all patients was re-entry [6]. Though, it is usual to perform 
multiple RF ablation in such patients, VT circuits can be changing as inflammation waxes and 
wanes.  
In  conclusion,  in  the  present  case  of  a  patient  with  sarcoidosis  and  cardiac  involvement, 
multiple sessions of radiofrequency catheter ablation of VT refractory to immunosuppressive 
therapy and traditional  anti-arrhythmic  drugs,  were effective  in  controlling  the  VT storms. 
Survival  after  a  life-threatening  illness  and  prolonged  hospitalization  in  a  distant  city 
(representing  major  financial,  emotional  and  social  stress  on  the  family)  was  especially 
gratifying  as  the  patient  was  able  to  resume  a  productive  career.                     
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